We enable the acceleration of life science research
and development in the pursuit of improved human health

About AiPharma

AiPharma is a biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases for unmet patient needs across a broad spectrum of infectious diseases. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that from improvements in established therapies. AiPharma is focused on the clinical and commercial development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).

Global Response Aid (GRA)

At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.








Dr.Alessandro Gadotti 
Chief Executive Officer 

Luca Longobardi
M&A Support


Abdulla Al Mansoori
Executive Director, MENA


Dr.Richard Kaszynski
Chief Medical Officer

Brett Wight
Chief Commercial Officer


Omar Arrab



John White
Group General Counsel


Mary O’Brien
VP Corporate Development

Dr. Ashraf Allam
Executive Chairman




December 28, 2021

Aditxt To Acquire AiPharma

(RTTNews) - Aditxt Inc. (ADTX) said it has signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly-owned subsidiary of AiPharma Group Ltd.

The share exchange agreement contemplates that the transaction would involve two steps.



December 02, 2021

AiPharma Signs Heads of Agreement to Acquire a Controlling Interest in a Pharmaceutical Business with Global Innovation, Manufacturing, Distribution Footprint, and Revenues in Excess of $450 Million 

The transaction is a strategic opportunity to position AiPharma as a fully integrated biotech innovation company


October 26, 2021

Potential COVID-19 treatment to wrap up Phase III trial

Pharmaceutical company Appili Therapeutics has reported the enrollment of the last patient in its Phase III clinical trial to investigate the effectiveness of oral drug Avigan/Reeqonus (favipiravir) to treat COVID-19. The firm recently entered a strategic alliance agreement with AiPharma to develop and advance the drug.


October 20, 2021

UK COVID-19 patients able to take GP prescribed medicine at home

COVID sufferers in the UK are now able to access a course of tablets from their GP to avoid the need for hospitalisation. AiPharma’s antiviral treatment, favipiravir, is currently taken orally over a course of 7-14 days.

avigan-3-e1633006406825 (1).jpg

October 28, 2021

Fast-Selling COVID-19 Treatment Avigan Made Available in UAE

AiPharma owned Global Response Aid (GRA) and Pharmax, both leading Dubai-based healthcare solutions providers, have partnered to supply the proven COVID-19 treatment, Avigan (Favipiravir), in the UAE. It allows patients with mild to moderate symptoms to be treated at home, easing the pressure on hospitals.


October 5, 2021

AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX).

DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement


September 29, 2021

AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics

AiPharma Global Holdings LLC ("AiPharma"), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company.


September 23, 2020

Avigan® Shows Promising Results in Treatment of COVID Patients in Japan

Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy's Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.


September 23, 2020

Anti-influenza drug Avigan® TabletMeets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

TOKYO, September 23, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet”